JP5646814B2 - Hcvを治療するためのリトナビルの組成物及び使用方法 - Google Patents
Hcvを治療するためのリトナビルの組成物及び使用方法 Download PDFInfo
- Publication number
- JP5646814B2 JP5646814B2 JP2008558506A JP2008558506A JP5646814B2 JP 5646814 B2 JP5646814 B2 JP 5646814B2 JP 2008558506 A JP2008558506 A JP 2008558506A JP 2008558506 A JP2008558506 A JP 2008558506A JP 5646814 B2 JP5646814 B2 JP 5646814B2
- Authority
- JP
- Japan
- Prior art keywords
- ritonavir
- sch
- dimethyl
- hcv
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Description
HCV治療法には幾つかの異なるタイプがある。最も一般的な治療法の1つは、α−インターフェロンとリバビリンの併用を含む。このタイプの治療でも、多くの患者はウイルス活性の低下を示さない。従って、HCV感染の治療における新しい有効な治療法を開発する必要は長く探られているが、解決されてはいない。
本発明によれば、リトナビルまたはその医薬的に許容され得る塩、エステル及びプロドラッグを共投与することを含むシトクロムP450モノオキシゲナーゼにより代謝される薬物(または、その医薬的に許容され得る塩、エステル及びプロドラッグ)の薬物動態を改善する組成物及び方法が開示されている。
液体はTecan EVOロボットシステムを用いて取り扱った。1μMの最終試験化合物濃度で0.5mg/ml ミクロソームタンパク質及び1mM NADPHと3回インキュベートした。プールしたヒト肝ミクロソーム(1mg/ml タンパク質)及びNADPHコファクター(2mM)を50mM リン酸緩衝液(pH7.4)中で作成した。VX−950またはSCH 503034のストック溶液(10mM)をDMSO中で調製した後、1:1 アセトニトリル/水で100μMまで希釈した。2mlの96ウェルプレートにおいて化合物の溶液を0、0.8または8μMのリトナビルを含有するNADPHコファクター溶液に添加した。生じた溶液を、予め37℃で10分間インキュベートしたミクロソーム(1:1)に添加した。サンプル(0.1ml)をTecan 4−スロットインキュベーターを用いて96ウェルプレートにおいて37℃で0、10、20及び30分間インキュベートした。各時点で、ロボットアームは複製プレートの1つを取り出し、各ウェルに1容量(100μl)の内部標準(0.05μM ブスピロン)を含むアセトニトリルを添加することにより反応を停止させた。すべてのプレートを3500rpmで30分間遠心し、上清を96ウェル注入プレートに移した。プレートは分析するまで4℃で保存した。
ヒト肝ミクロソームの代わりにラット肝ミクロソームを使用する以外は実施例1の手順を用いると、リトナビルの存在が表2に示すような様式でVX−950及びSCH 503034の代謝を阻害した。
VX−950の薬物動態挙動を、Sprague−Dawley由来ラット(n=3/群)に5mg/kgを1回静脈または経口投与してキャラクタライズした。3匹のラットからなる別の群には、5mg/kgのVX−950と5mg/kgのリトナビルを共に経口投与した。VX−950(±リトナビル)は、経口(±リトナビル)及び静脈投与のために10% DMSO:90% PEG−400ビヒクル中5mg/mL溶液として調製した。1mL/kgの静脈用量はイソフルラン麻酔下でラットの頸静脈にゆっくりしたボーラス(〜1分間)として投与した。1ml/kgの経口用量(±リトナビル)は胃管栄養法により投与した。一連の血液サンプルを投与してから0.1(IVのみ)、0.25、0.5、1、1.5、2、3、4、6及び8時間後に各動物の尾静脈から採取した。採取してから直ちにヘパリシン処理したサンプルを氷上に置いた。遠心して血漿を分離し、次の分析のために凍結保存した。
VX−950の代わりにSCH 503034を使用する以外は実施例3の手順を用いると、図3及び以下に示すように以下の平均(±標準誤差)血漿レベルが得られ、リトナビルと共投与するとSCH 503034の血漿レベルが実質的に上昇することが判明した。
Claims (1)
- 3−[2−(3−tert−ブチル−ウレイド)−3,3−ジメチル−ブチリル]−6,6−ジメチル−3−アザ−ビシクロ[3.1.0]ヘキサン−2−カルボン酸(2−カルバモイル−1−シクロブチルメチル−2−オキソ−エチル)−アミド(SCH 503034)またはその塩、及びリトナビルまたはその塩を含む共投与される医薬組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US77950106P | 2006-03-06 | 2006-03-06 | |
US60/779,501 | 2006-03-06 | ||
PCT/US2007/063408 WO2007103934A2 (en) | 2006-03-06 | 2007-03-06 | Compositions and methods of use of ritonavir for treating hcv |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014150456A Division JP5779271B2 (ja) | 2006-03-06 | 2014-07-24 | Hcvを治療するためのリトナビルの組成物及び使用方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2009529537A JP2009529537A (ja) | 2009-08-20 |
JP5646814B2 true JP5646814B2 (ja) | 2014-12-24 |
Family
ID=38475808
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008558506A Expired - Fee Related JP5646814B2 (ja) | 2006-03-06 | 2007-03-06 | Hcvを治療するためのリトナビルの組成物及び使用方法 |
JP2014150456A Expired - Fee Related JP5779271B2 (ja) | 2006-03-06 | 2014-07-24 | Hcvを治療するためのリトナビルの組成物及び使用方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014150456A Expired - Fee Related JP5779271B2 (ja) | 2006-03-06 | 2014-07-24 | Hcvを治療するためのリトナビルの組成物及び使用方法 |
Country Status (7)
Country | Link |
---|---|
US (2) | US20070207122A1 (ja) |
EP (1) | EP2007381A4 (ja) |
JP (2) | JP5646814B2 (ja) |
CN (1) | CN101460166B (ja) |
CA (1) | CA2645684A1 (ja) |
MX (1) | MX2008011429A (ja) |
WO (1) | WO2007103934A2 (ja) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070287664A1 (en) * | 2006-03-23 | 2007-12-13 | Schering Corporation | Combinations of HCV protease inhibitor(s) and CYP3A4 inhibitor(s), and methods of treatment related thereto |
WO2011009961A1 (en) * | 2009-07-24 | 2011-01-27 | Virologik Gmbh | Combination of proteasome inhibitors and anti-hepatitis medication for treating hepatitis |
US20130289381A1 (en) | 2011-11-02 | 2013-10-31 | Seno Medical Instruments, Inc. | Dual modality imaging system for coregistered functional and anatomical mapping |
US10433732B2 (en) | 2011-11-02 | 2019-10-08 | Seno Medical Instruments, Inc. | Optoacoustic imaging system having handheld probe utilizing optically reflective material |
US11191435B2 (en) | 2013-01-22 | 2021-12-07 | Seno Medical Instruments, Inc. | Probe with optoacoustic isolator |
US9757092B2 (en) | 2011-11-02 | 2017-09-12 | Seno Medical Instruments, Inc. | Method for dual modality optoacoustic imaging |
WO2020048826A1 (en) | 2018-09-03 | 2020-03-12 | Bayer Aktiengesellschaft | 5-substituted 1-oxa-3,9-diazaspiro[5.5]undecan-2-one compounds |
WO2020048829A1 (en) | 2018-09-03 | 2020-03-12 | Bayer Aktiengesellschaft | 3,9-diazaspiro[5.5]undecane compounds |
WO2020048830A1 (en) | 2018-09-03 | 2020-03-12 | Bayer Aktiengesellschaft | 5-aryl-3,9-diazaspiro[5.5]undecan-2-one compounds |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6000A (en) * | 1849-01-02 | Abunah s | ||
US216325A (en) * | 1879-06-10 | Improvement in portable minjng-flumes | ||
US5024A (en) * | 1847-03-20 | Steam-cylindee | ||
US5552558A (en) * | 1989-05-23 | 1996-09-03 | Abbott Laboratories | Retroviral protease inhibiting compounds |
DE69334250D1 (de) * | 1992-12-29 | 2009-01-29 | Abbott Lab | Verfahren und Intermediate zur Herstellung von retroviralen Proteasehemmern |
US6037157A (en) * | 1995-06-29 | 2000-03-14 | Abbott Laboratories | Method for improving pharmacokinetics |
US5830905A (en) * | 1996-03-29 | 1998-11-03 | Viropharma Incorporated | Compounds, compositions and methods for treatment of hepatitis C |
PL206255B1 (pl) * | 2000-07-21 | 2010-07-30 | Dendreon Corporationdendreon Corporation | Inhibitor proteazy wirusa zapalenia wątroby C, zawierająca go kompozycja farmaceutyczna i zastosowanie inhibitora do wytwarzania leku do leczenia chorób związanych z HCV oraz zastosowanie do wytwarzania kompozycji do stosowania w kombinowanej terapii |
SV2003000617A (es) * | 2000-08-31 | 2003-01-13 | Lilly Co Eli | Inhibidores de la proteasa peptidomimetica ref. x-14912m |
DK1677827T3 (da) * | 2003-10-27 | 2009-03-30 | Vertex Pharma | Kombinationer til HCV-behandling |
WO2005107745A1 (en) * | 2004-05-06 | 2005-11-17 | Schering Corporation | An inhibitor of hepatitis c |
TWI389688B (zh) * | 2004-06-08 | 2013-03-21 | Vertex Pharma | Vx-950之形態與調配物及其製備方法與用途 |
SG155967A1 (en) * | 2004-10-01 | 2009-10-29 | Vertex Pharma | Hcv ns3-ns4a protease inhibition |
-
2007
- 2007-03-06 JP JP2008558506A patent/JP5646814B2/ja not_active Expired - Fee Related
- 2007-03-06 WO PCT/US2007/063408 patent/WO2007103934A2/en active Application Filing
- 2007-03-06 CN CN200780007930.8A patent/CN101460166B/zh not_active Expired - Fee Related
- 2007-03-06 US US11/682,668 patent/US20070207122A1/en not_active Abandoned
- 2007-03-06 MX MX2008011429A patent/MX2008011429A/es active IP Right Grant
- 2007-03-06 CA CA002645684A patent/CA2645684A1/en not_active Abandoned
- 2007-03-06 EP EP07758000A patent/EP2007381A4/en not_active Ceased
-
2010
- 2010-12-02 US US12/958,899 patent/US8901157B2/en not_active Expired - Fee Related
-
2014
- 2014-07-24 JP JP2014150456A patent/JP5779271B2/ja not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
EP2007381A2 (en) | 2008-12-31 |
CN101460166B (zh) | 2014-11-19 |
WO2007103934A3 (en) | 2008-11-06 |
CA2645684A1 (en) | 2007-09-13 |
JP2014237678A (ja) | 2014-12-18 |
US20110091423A1 (en) | 2011-04-21 |
WO2007103934A2 (en) | 2007-09-13 |
JP5779271B2 (ja) | 2015-09-16 |
MX2008011429A (es) | 2008-09-18 |
CN101460166A (zh) | 2009-06-17 |
US8901157B2 (en) | 2014-12-02 |
US20070207122A1 (en) | 2007-09-06 |
JP2009529537A (ja) | 2009-08-20 |
EP2007381A4 (en) | 2010-11-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5779271B2 (ja) | Hcvを治療するためのリトナビルの組成物及び使用方法 | |
JP5539363B2 (ja) | インターフェロンおよびリバビリンとのhcvns3プロテアーゼ阻害剤の組合せ | |
US20110171174A1 (en) | Synergistic Combinations of a Macrocyclic Inhibitor of HCV and a Nucleoside | |
TW201532606A (zh) | 使用化合物之組合治療c型肝炎病毒感染 | |
JP2008530124A (ja) | フラビウイルス感染症を処置または予防するための組成物および方法 | |
US20080075695A1 (en) | Combination therapy method for treating hepatitis c virus infection and pharmaceutical compositions for use therein | |
ZA200602912B (en) | Combination therapy for HCV infection | |
JP2012514605A (ja) | Hcvおよびhiv感染の治療への使用におけるシクロスポリン誘導体 | |
WO2010031832A9 (en) | Synergistic combinations of a macrocyclic inhibitor of hcv and a thiophene-2-carboxylic acid derivative | |
JP2014509630A (ja) | B型肝炎ウイルス単独の感染症またはデルタ肝炎ウイルスとの複合感染症および付随する肝疾患の治療 | |
EP3370723B1 (en) | Treatment of hepatitis delta virus infection | |
US20220023287A1 (en) | Treatment of hepatitis delta virus infection | |
CN114025760B (zh) | 改进的用eyp001的治疗 | |
JP2015526504A (ja) | Hcvの大環状プロテアーゼ阻害剤と、非ヌクレオシドhcv阻害剤と、リトナビルとの組み合わせ | |
WO2008004653A1 (fr) | Agent prophylactique ou thérapeutique pour une maladie virale | |
CN117202905A (zh) | Fxr激动剂和ifn用于治疗hbv感染的协同效果 | |
US9763901B2 (en) | Treatment of hepatitis C using histone deacetylase inhibitors | |
US20150174194A1 (en) | Methods for treating liver transplant recipients | |
JP2014509628A (ja) | C型肝炎ウイルス感染症を治療するためのアリスポリビル | |
US10201541B1 (en) | Compositions and methods for treating HCV | |
JP2017514834A (ja) | Hcv感染症を治療するための組合せ療法 | |
JP2004155777A (ja) | C型慢性肝炎治療剤 | |
EA046230B1 (ru) | Синергическое действие eyp001 и ifn при лечении инфекции hbv | |
TW201536297A (zh) | C型肝炎病毒感染之新治療方法 | |
JP2014510772A (ja) | アリスポリビルを用いたc型肝炎ウイルス感染症の治療 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100223 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120918 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20121101 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20121204 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20121212 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20121219 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130306 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A712 Effective date: 20130701 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130822 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20140325 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140724 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20140902 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20141104 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20141106 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5646814 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |